Erin M. Burns, PhD, MSPH


Advanced Practice Providers Are Poised to Boost Community Involvement in Clinical Trials

July 19th 2021

For those in the community setting, several barriers to clinical research prevent advanced care providers and their patients from taking part in experimental therapies.

Pharmacy Operations Can Enhance Reimbursement Picture for Oncology Drugs

June 6th 2020

Pharmacists can play a role in the drug reimbursement process for oncology products, which are among the most expensive of all pharmaceuticals.

Automated Prior Authorization Catches On

March 17th 2020

In January, America’s Health Insurance Plans in collaboration with payers representing 60 million covered individuals launched the Fast Prior Authorization Technology Highway to improve the prior authorization process.

Navigating the Changing Landscape in HER2-Positive Breast Cancer

March 9th 2020

The paradigm for treating patients with HER2-positive breast cancer is changing throughout the spectrum of the disease as a result of recent clinical trial findings regarding novel and established treatment regimens, according to Sara A. Hurvitz, MD

Gene Signatures Predict for Radiation Response in Breast Cancer

January 28th 2020

Recent studies have demonstrated that somatic mutations of ATM denote greater response to radiation therapy and that gene patterns may help predict the timing of recurrence following radiation.

CDK4/6 Inhibitors Explored in KRAS-Mutant Cancers

October 31st 2017

A new generation of more selective inhibitors of CDK4 and CDK6 has entered the clinic in combination therapies for patients with breast cancer. These agents also are being investigated in patients with KRAS-mutant malignancies.

EZH2 Emerges as Epigenetic Target

September 22nd 2017

EZH2 have been frequently observed in cancer, and small molecule inhibitors have been developed against the enzymatic activity of EZH2, with evidence of clinical activity in early-phase trials.

Biomarker Basics: A Look at MSI's Growing Role

August 2nd 2017

The recent approval of 2 immunotherapies for the treatment of certain patients with tumors that exhibit microsatellite instability has propelled the emerging biomarker into clinical practice, prompting calls for broader genetic testing.